One major limitation was the missing confirmation of rejection episodes by renal biopsy in about 50 % of patients and controls. It is likely that an increase in serum creatinine level during the test phase of an investigational drug was assumed to be a rejection episode by the responsible physician. Without doubt, it was more tempting to perform such clinical interpretation in the treatment group.